Effect of Dexamethasone Implant on Subfoveal Choroidal Thickness in Early Period in Vitrectomized Eyes with Diabetic Macular Edema

Table 1

Demographic characteristics of the groups, hypertension history, anticoagulant and antiplatelet drug use, hemoglobin A1c levels, and previous anti-VEGF injections.

		Group 1 (with DME)					Group 2 (without DME)			value
		Mean ± SD/n−%			Median	Mean ± SD/n−%			Median
Age (year)		54.2	±	4.8	55.0	53.8	±	4.7	54.0	0.872	^m
Gender	Male	20		41.7%		23		47.9%		0.751	^X²
	Female	28		58.3%		25		52.1%
Hypertension		28		58.3%		26		54.1%		0.889	^X²
Anticoagulant drug use		16		33.3%		14		29.1%		0.712	^X²
Antiplatelet drug use		24		50.0%		19		39.5%		0.442	^X²
Hemoglobin A1c (%)		7.67	±	0.35	7.75	7.41	±	0.33	7.61	0.714	^m
Total number of anti-VEGF injections		3.83	±	0.78	4.00	1.97	±	0.42	2.00	0.000	^m

^mMann–Whitney U test; ^X²chi-square test; ^wWilcoxon test; SD, standard deviation; HbA1c, hemoglobin A1c; DME, diabetic macular edema; VEGF, vascular endothelial growth factor.